Lobbying registration dated 2026-03-16
Registrant: Michael Casia
Client: Organon Canada Inc.
Targeted institutions:
Correctional Service of Canada (CSC)
Innovation, Science and Economic Development Canada (ISED)
House of Commons
National Defence (DND)
Indigenous Services Canada (ISC)
Global Affairs Canada (GAC)
Senate of Canada
Health Canada (HC)
Legislative bills: S-243
Government funding received:
Lobbying activity details:
To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
To advocate for the adoption of Bill S-243 ("An Act to establish a national framework for women's health in Canada").
To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.